Video-capsule endoscopy gastric and small bowel transit time and completeness of the examination in patients with diabetes mellitus

Triantafyllou, Konstantinos; Kalantzis, C.; Papadopoulos, Angelos; Apostolopoulos, Periklis; Rokkas, Theodore; Kalantzis, Nikolaos; Ladas, Spiros D.

doi:10.1016/j.dld.2007.01.024

Cited by 88 publications

(56 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We know that CE fails to reach the cecum in 15-20% of the procedures [5,14], but higher rates of incomplete enteroscopy have been reported [23]. Gastric retention and delayed gastric emptying are associated with failure of the capsule to reach the colon [15,16].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Effect of Metoclopramide in Capsule Enteroscopy

et al. 2009

View full text Add to dashboard Cite

Clinical utility of prokinetics in capsule endoscopy (CE) is not clearly established. The objective of this prospective, randomized, single-blind, controlled trial was to determine if metoclopramide is useful in CE by increasing the rate of complete enteroscopy. Ninety-five patients referred for CE were randomized to no metoclopramide (group B, n = 48) or 10 mg metoclopramide (group A, n = 47). Complete enteroscopy was possible in 38 patients of group A (80.9%) and 37 of group B (77.1%) (P = 0.422) with two cases of gastric retention in group B (4.2%; P = 0.253). Median gastric transit time was 26 min (1-211) in group A and 28 min (4-200) in group B (P = 0.511). Mean small bowel transit time, calculated after excluding 20 patients with incomplete enteroscopy, was similar in both groups (221.2 ± 89 min vs. 256 ± 82.2 min; P = 0.083). There were also no differences in the total number of findings (group A 4.5 ± 4.7; group B 4.7 ± 3.7, P = 0,815). Administration of 10 mg metoclopramide orally 15 min before capsule ingestion did not significantly increase the rate of total enteroscopies and had no effect on transit times. It also did not modify CE diagnostic yield.

show abstract

Section: Discussionmentioning

confidence: 99%

“…However, the diagnostic yield depends on the enteroscopy completion rates to the cecum. Incomplete enteroscopy, reported to occur in 15-20% of patients [5,14], is affected by gastric transit time [15].…”

Section: Background and Aimsmentioning

confidence: 99%

The Effect of Metoclopramide in Capsule Enteroscopy

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Do czynników zwiększających ryzyko przeprowadzenia badań niekompletnych należą: zabiegi chirurgiczne w obrębie jelita cienkiego w wywiadzie, hospitalizacje, złe lub umiarkowane przygotowanie przewodu pokarmowego do badania, czas tranzytu żołądkowego przekraczający 45 minut [10], a także cukrzyca [11]. Stosowanie erytromycyny jako czynnika prokinetycznego jest nadal kontrowersyjne, ponieważ lek ten co prawda przyspiesza opróżnianie żołądkowe, ale może opóźniać tranzyt jelitowy.…”

Section: Wstępunclassified

Utility of capsule endoscopy in children and youth – own experience

Szaflarska-Popławska¹,

Popławski²,

Mierzwa³

2012

View full text Add to dashboard Cite

“…Several studies have been performed to study the transit of particles through the small intestine and particularly through the colon; however, results of these studies are controversial (6,7). Several studies have shown that the time taken for orocecal and colorectal transit is longer for diabetic patients than for non-diabetic (ND) individuals (7)(8)(9). However, some other studies did not show any significant difference between diabetic and healthy individuals with respect to gastrointestinal transit (10,11).…”

Section: Introductionmentioning

confidence: 98%

“…However, some other studies did not show any significant difference between diabetic and healthy individuals with respect to gastrointestinal transit (10,11). Currently, radiopaque markers are used for studying gastrointestinal transit (6,9,12,13); these markers allow the characterization of the transit time through each part of the gastrointestinal tract by using different methods and formulas and help determine the total transit time (14). This is the standard method, based on which the accuracy of other new methods is evaluated (15)(16)(17)(18)(19).…”

Section: Introductionmentioning

confidence: 99%

Transit of radiopaque particles through the gastrointestinal tract: comparison between type 2 diabetes patients and healthy individuals

Jorge

Matos

Machado

et al. 2012

Rev. esp. enferm. dig.

View full text Add to dashboard Cite

Background/aims: some studies have reported controversial results when comparing the gastrointestinal transit between diabetic and healthy individuals. Therefore, we compared the gastrointestinal transit of radiopaque particles between diabetic and non-diabetic healthy individuals.Methods: abdominal radiographies were performed for 45 type 2 diabetes mellitus patients and 35 healthy individuals (gender and age similar for both groups) at 24 and 72 h after they ingested radiopaque particles. The mean number of particles in the colon was compared for both groups. The data were expressed as mean and standard deviation values.Results: at 24 h, the total number of particles in the colon did not differ significantly for the diabetic and non-diabetic individuals. At 72 hours, the distribution in the diabetic and non-diabetic individuals was as follows: right colon, 0.44 ± 0.88 and 0.26 ± 0.7, respectively (p = 0.8); left colon, 2.6 ± 4.2 and 0.49 ± 1.3 (p < 0.003); and rectosigmoid colon, 2.65 ± 3.8 and 0.80 ± 1.5 (p < 0.005).The mean number of radiopaque particles in the entire colon was 5.7 ± 7.1 and 1.5 ± 2.7 for diabetic and non-diabetic individuals, respectively (p < 0.001).Conclusions: the number of radiopaque particles in the colon did not significantly differ for the diabetic and non-diabetic individuals at 24 h after ingestion but was significantly greater in diabetic individuals at 72 h after ingestion. At 72 h, the mean number of radiopaque particles in the left and rectosigmoid colon were significantly higher in the diabetics than in the non-diabetic individuals.Key words: Transit of radiopaque particles. Diabetes mellitus. INTRODUCTIONGastrointestinal alterations seem to be common in patients with type 2 diabetes mellitus (DM) (1-3), although studies contradicting these observations also exist (4). Some studies have shown that gastrointestinal transit is altered in diabetic patients (5). Several studies have been performed to study the transit of particles through the small intestine and particularly through the colon; however, results of these studies are controversial (6,7). Several studies have shown that the time taken for orocecal and colorectal transit is longer for diabetic patients than for non-diabetic (ND) individuals (7-9). However, some other studies did not show any significant difference between diabetic and healthy individuals with respect to gastrointestinal transit (10,11). Currently, radiopaque markers are used for studying gastrointestinal transit (6,9,12,13); these markers allow the characterization of the transit time through each part of the gastrointestinal tract by using different methods and formulas and help determine the total transit time (14). This is the standard method, based on which the accuracy of other new methods is evaluated (15)(16)(17)(18)(19). Some authors believe that calculating gastrointestinal transit time by using different methods and formulas may produce different outcomes (14). Similarly, the physical characteristics of radiopaque particles can also influence...

show abstract

Video-capsule endoscopy gastric and small bowel transit time and completeness of the examination in patients with diabetes mellitus

Cited by 88 publications

References 22 publications

The Effect of Metoclopramide in Capsule Enteroscopy

The Effect of Metoclopramide in Capsule Enteroscopy

Utility of capsule endoscopy in children and youth – own experience

Transit of radiopaque particles through the gastrointestinal tract: comparison between type 2 diabetes patients and healthy individuals

Contact Info

Product

Resources

About